BRAF and melanoma: BRIM 8 was an international, double-blinded, placebo-controlled phase III trial looking at another adjuvant BRAF V600 inhibitor—vemurafenib—in 498 patients with AJCC Stage IIC, IIIA, IIIB, or IIIC fully resected melanoma [37].